Albert Lowe
Stock Analyst at Craig-Hallum
(2.23)
# 2,803
Out of 5,051 analysts
9
Total ratings
33.33%
Success rate
16.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Initiates: Buy | $50 | $31.80 | +57.23% | 1 | Jun 17, 2025 | |
| ATOS Atossa Therapeutics | Initiates: Buy | $4 | $0.85 | +371.64% | 1 | Jun 5, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $6 | $2.17 | +176.50% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $1.42 | +885.92% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $3.25 | +238.46% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $2.22 | +260.36% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $1.80 | +122.22% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $1.34 | +347.76% | 1 | May 13, 2024 |
Neurogene
Jun 17, 2025
Initiates: Buy
Price Target: $50
Current: $31.80
Upside: +57.23%
Atossa Therapeutics
Jun 5, 2025
Initiates: Buy
Price Target: $4
Current: $0.85
Upside: +371.64%
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $2.17
Upside: +176.50%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $1.42
Upside: +885.92%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $3.25
Upside: +238.46%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $2.22
Upside: +260.36%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $1.80
Upside: +122.22%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.34
Upside: +347.76%